Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Arnd Schwebig"'
Autor:
Peter Reinhardt, Christian Seidl, Hubert Schrezenmeier, Heike Bialleck, Erhard Seifried, Arnd Schwebig, Sreekanth Gattu, Susanne Brauninger, Petra S. A. Becker, Beate Luxembourg, Halvard Bonig, Chrysanthi Tsamadou, Natalia Kaliakina, Pritibha Singh, Miriam Schulz, Joannis Mytilineos, M Wiesneth
Publikováno v:
Transfusion. 56:3055-3064
BACKGROUND Biosimilar granulocyte-colony-stimulating factors (G-CSFs) have been available in the European Union since 2008, and Sandoz' biosimilar filgrastim was approved in the United States in March 2015 for all of the reference product's indicatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a043be3ffa6a24b87fb1f6327e5491d2
https://doi.org/10.1111/trf.13853
https://doi.org/10.1111/trf.13853
Autor:
Adanna Davis, Goran Babic, Heike Woehling, Marco Matucci-Cerinic, Arnd Schwebig, Hendrik Schulze-Koops, Yannick Allanore, Maya H Buch, Johann Poetzl, Eugeniusz J. Kucharz, Arthur Kavanaugh
Publikováno v:
RMD Open
Matucci-Cerinic, M, Allanore, Y, Kavanaugh, A, Buch, M H, Schulze-Koops, H, Kucharz, E J, Woehling, H, Babic, G, Poetzl, J, Davis, A & Schwebig, A 2018, ' Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis : 24-week results from the comparative phase III, randomised, double-blind EQUIRA study ', RMD Open, vol. 4, no. 2, pp. e000757 . https://doi.org/10.1136/rmdopen-2018-000757
Matucci-Cerinic, M, Allanore, Y, Kavanaugh, A, Buch, M H, Schulze-Koops, H, Kucharz, E J, Woehling, H, Babic, G, Poetzl, J, Davis, A & Schwebig, A 2018, ' Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis : 24-week results from the comparative phase III, randomised, double-blind EQUIRA study ', RMD Open, vol. 4, no. 2, pp. e000757 . https://doi.org/10.1136/rmdopen-2018-000757
ObjectivesTo demonstrate the equivalent efficacy and compare the safety and immunogenicity of an etanercept biosimilar, GP2015, with reference etanercept (ETN) in patients with moderate-to-severe, active rheumatoid arthritis (RA), characterised by an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1604d9f4bf68801fa9506c57ffcc142
https://eprints.whiterose.ac.uk/139742/3/e000757.full.pdf
https://eprints.whiterose.ac.uk/139742/3/e000757.full.pdf
Publikováno v:
Biodrugs
Background Biosimilars provide safety, purity, and potency similar to those of a reference biologic product. Methods An array of protein analytical techniques was used to compare the physicochemical properties of proposed biosimilar filgrastim (EP200
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e048f303eeebdd13793b8f28b659d6c6
https://doi.org/10.1007/s40259-015-0124-7
https://doi.org/10.1007/s40259-015-0124-7
Publikováno v:
Transfusion. 55:430-439
Biosimilars are approved biologics with comparable quality, safety, and efficacy to a reference product. Unlike generics, which are chemically manufactured copies of small-molecule drugs with relatively simple chemical structures, the biosimilar desi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::55e2c3d9326e09155250fe3093acf10c
https://doi.org/10.1111/trf.12770
https://doi.org/10.1111/trf.12770
Publikováno v:
Transfusion
Biosimilars are approved biologics with comparable quality, safety, and efficacy to a reference product. Unlike generics, which are chemically manufactured copies of small-molecule drugs with relatively simple chemical structures, the biosimilar desi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::8b655d638018caefcc484139a1732742
http://europepmc.org/articles/PMC4497358
http://europepmc.org/articles/PMC4497358
Publikováno v:
European Journal of Endocrinology. 162:1051-1058
ObjectiveTwo strengths of a novel ready-to-use liquid preparation of the recombinant human GH (rhGH) Omnitrope were developed to increase the convenience for the patients.DesignOmnitrope 3.3 mg/ml solution or Omnitrope 6.7 mg/ml solution was compared
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40aa03a817873f6695de52a64343aeef
https://doi.org/10.1530/eje-09-1101
https://doi.org/10.1530/eje-09-1101
Autor:
Pedro Gascon, Roumen Nakov, Kimberly L. Blackwell, Arnd Schwebig, Vladimir Semiglazov, Stefan Krämer, Nadia Harbeck
Publikováno v:
Blood. 124:5133-5133
Introduction: Biosimilars are biologics which have demonstrated highly similar safety, potency and purity to an originator product. Several biosimilars of recombinant human filgrastim, based on the originator Neupogen®, have become available in Euro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::766d5b90254e3e1350acda5effe88e4a
https://doi.org/10.1182/blood.v124.21.5133.5133
https://doi.org/10.1182/blood.v124.21.5133.5133